Vilanterol

Vilanterol (INN, USAN) is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).[1]

Vilanterol
Clinical data
License data
ATC code
Legal status
Legal status
  • UK: POM (Prescription only)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard100.217.751
Chemical and physical data
FormulaC24H33Cl2NO5
Molar mass486.43 g·mol−1
3D model (JSmol)

Vilanterol is available in following combinations:

See also

  • Salmeterol—a long-acting β2 adrenoreceptor agonist (LABA) with a similar backbone.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.